1. Poland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Celon Pharma SA

Celon Pharma SA

19.50
PLN
+0.12
(+0.62%)
2.12EPS
9.29P/E
1.06BMarket Cap
Nov 18Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.39
2.86
2.38
2.78
2.27
3.01
3.63
3.17
3.22
3.3
- -
- -
Basic EPS, GAAP
0.83
0.84
0.57
0.66
0.27
-0.02
-0.25
-0.77
-0.55
-0.64
-1.49
2.12
Free Cash Flow per Basic Share
0.17
-0.01
-0.13
-0.87
-1.56
-0.62
0.06
-0.76
-0.81
-0.63
0.45
-0.58
Dividend per Share
0.12
0.1
0.17
0.17
0.16
0.08
0.07
0.29
0.09
0.08
- -
- -
Book Value per Share
2.24
8.94
9.77
9.97
9.89
7.62
11.87
9.4
8.73
8.27
6.74
9.25
Tangible Book Value per Share
2.17
8.87
9.72
9.81
9.75
6.71
11.23
8.97
8.43
8.12
6.74
8.78
Basic Weighted Avg Shares
45
45
45
45
45
45
47
51
51
54
53
52
Sales/Revenue/Turnover
108
129
107
125
102
135
170
162
164
178
- -
- -
Operating Margin (%)
42.85
36.41
24.29
28.21
6.08
-4.97
-8.02
-23.47
-18.86
-20.73
- -
- -
Depreciation Expense
8
13
17
17
21
32
41
44
50
52
- -
- -
Net Income, GAAP
37
38
26
30
12
-1
-12
-39
-28
-34
-79
111
Effective Tax Rate (%)
20.05
19.19
17.14
20.79
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
34.57
29.36
23.91
23.71
11.67
-0.68
-6.85
-24.26
-17.11
-19.4
- -
- -
Working Capital
8
256
236
194
118
5
192
121
103
94
- -
34
LT Debt
4
3
- -
- -
- -
9
8
7
6
8
- -
117
Total Equity
101
403
440
449
445
345
554
480
446
445
363
499
Return on Invested Capital (%)
- -
14.49
5.06
6.33
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
14.68
6.11
6.89
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
15.02
6.08
6.68
2.67
-0.23
-2.59
-7.6
-6.08
-7.73
-19.63
25.07

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
21
12
LT Borrowings
- -
1
78
LT Finance Leases
- -
32
39
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
1,096
1,065
1,063

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
105
125
Cash, Cash Equivalents & STI
- -
2
34
Accounts Receivable, Net
- -
53
42
Inventories
- -
25
24
Total Current Liabilities
63
108
91
Payables & Accruals
- -
- -
- -
ST Debt
- -
21
12
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.89%
4.36%
-18.41%
Free Cash Flow
-57.38%
-374.92%
-169.88%
Net Income, GAAP
134.65%
305.72%
130.39%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35
54
51
38
178
2025
49
51
52
- -
- -
2026
57
49
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.31
-0.16
1.06
-1.26
-0.64
2025
-0.47
-0.61
0.07
-0.46
-1.49
2026
3.06
-0.62
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Maciej Wieczorek
Full Time Employees
562
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ogrodowa 2A Lomianki MZ Poland 05-092
IPO Date
Oct 17, 2016
Website
celonpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Celon Pharma S.A. (CLN.WA) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for central nervous system disorders, rare diseases, and oncology. The company offers a diversified pipeline of proprietary small molecule drug candidates, including kinase inhibitors such as CPL207 for Parkinson's disease and CPL500 for ALS, as well as CPL302 for breast cancer and other HER2-positive tumors; it also provides contract development and manufacturing services through its CDMO division, encompassing API synthesis, formulation development, and analytical services for third-party clients. Founded in 2002 and headquartered in Kielpin, near Warsaw, Poland, Celon Pharma operates primarily in Europe with expanding clinical trials in the United States and partnerships targeting global markets in neurology, oncology, and rare genetic disorders. In recent developments, Celon Pharma advanced its Phase II clinical trial for CPL207, a selective DYRK1A inhibitor, reporting positive preliminary efficacy data in Parkinson's patients in late 2024, positioning it as a potential first-in-class therapy. The company secured a strategic licensing agreement with Mediolanum, an Italian pharma firm, in 2024 for the development and commercialization of its kinase inhibitor portfolio in select European territories, bolstering its regional expansion. Additionally, Celon Pharma completed a PLN 100 million capital raise through a rights issue in mid-2025 to fund ongoing Phase II/III trials and CDMO capacity upgrades, while inaugurating a new GMP-certified manufacturing facility in 2025 to support both proprietary products and contract services.